PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear fact...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-07, Vol.11 (7), p.949
Main Authors: Ghoneum, Alia, Said, Neveen
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
Angiogenesis
Cancer therapies
Cell cycle
Cell growth
Chromosomes
Enzymes
Growth factors
Kinases
Lymphocytes B
Malignancy
Medical prognosis
Metabolism
Metastasis
Mutation
NF-κB protein
Ovarian cancer
Protein expression
Proteins
Rapamycin
Review
Survival analysis
TOR protein
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11070949